{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:00:40Z","timestamp":1780329640905,"version":"3.54.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Despite their profound clinical impact and high mortality, acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) still lack any effective or standardized treatment strategies. This manuscript describes the rationale and design of a randomized, multicenter, open-label Phase III clinical trial evaluating the efficacy of intravenous immunoglobulin (IVIG) compared with usual care in hospitalized patients with AE-IPF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This trial will enroll 196 patients across eight different sites in Greece. Inclusion criteria are designed to identify patients with AE-IPF according to the American Thoracic Society definition, while excluding those with cardiac decompensation or pulmonary embolism. The primary endpoint is a composite of all-cause in-hospital mortality or the need for intubation. Secondary endpoints include all-cause mortality at 30 and 90 days, hospital readmission or a new AE-IPF episode within 90 days, and the change in the PaO\n                      <jats:sub>2<\/jats:sub>\n                      \/FiO\n                      <jats:sub>2<\/jats:sub>\n                      ratio from hospital admission to discharge.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Based on the concept that patients with IPF frequently demonstrate impaired cellular and humoral immunity, and inflammation and\/or immune dysregulation may contribute to AE-IPF pathogenesis, there is a strong rationale for evaluating the therapeutic usefulness of IVIG in this setting. Retrospective data indicate that IVIG could provide clinical benefit in AE-IPF, potentially through its anti-inflammatory and immunomodulatory effects. In this trial, IVIG will be administered as an adjunct to usual care, which includes pulse corticosteroids, broad-spectrum antibiotics, prophylactic anticoagulation, and oxygen therapy. This intervention has the potential to significantly influence current treatment strategies for AE-IPF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      , identifier NCT05745545.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1777564","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:16:51Z","timestamp":1777954611000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Design of the MERCURION-IPF trial \u2013 intravenous immunoglobulin for the treatment of acute exacerbations of idiopathic pulmonary fibrosis"],"prefix":"10.3389","volume":"17","author":[{"given":"Vasilina","family":"Sotiropoulou","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, University Hospital of Patras","place":["Patras, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotios","family":"Sampsonas","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, University Hospital of Patras","place":["Patras, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Vasarmidi","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular and Cellular Pulmonology, Department of Respiratory Medicine, University of Crete","place":["Heraklion, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Antoniou","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular and Cellular Pulmonology, Department of Respiratory Medicine, University of Crete","place":["Heraklion, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena","family":"Gogali","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, University Hospital of Ioannina","place":["Ioannina, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Kostikas","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, University Hospital of Ioannina","place":["Ioannina, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotios","family":"Drakopanagiotakis","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Medical School, Democritus University of Thrace","place":["Alexandroupolis, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paschalis","family":"Steiropoulos","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Medical School, Democritus University of Thrace","place":["Alexandroupolis, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Margaritopoulos","sequence":"additional","affiliation":[{"name":"Pulmonary Department, George Papanikolaou Hospital, Aristotle University of Thessaloniki","place":["Thessaloniki, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Porpodis","sequence":"additional","affiliation":[{"name":"Pulmonary Department, George Papanikolaou Hospital, Aristotle University of Thessaloniki","place":["Thessaloniki, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Daniil","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, University Hospital of Larissa","place":["Larissa, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Tomos","sequence":"additional","affiliation":[{"name":"5th Pulmonary Department, \u2018SOTIRIA\u2019 Chest Diseases Hospital of Athens","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilias","family":"Papanikolaou","sequence":"additional","affiliation":[{"name":"Pulmonary Department, Corfu General Hospital","place":["Corfu, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios","family":"Tzilas","sequence":"additional","affiliation":[{"name":"2nd Respiratory Medicine Department, Attikon University Hospital, National and Kapodistrian University of Athens","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stelios","family":"Loukides","sequence":"additional","affiliation":[{"name":"2nd Respiratory Medicine Department, Attikon University Hospital, National and Kapodistrian University of Athens","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argyrios","family":"Tzouvelekis","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, University Hospital of Patras","place":["Patras, Greece"]},{"name":"Department of Internal Medicine, Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine","place":["New Haven, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201604-0801ci","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report","volume":"194","author":"Collard","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0071-2018","article-title":"Acute exacerbations of progressive-fibrosing interstitial lung diseases","volume":"27","author":"Kolb","year":"2018","journal-title":"Eur Respir Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01760-2019","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation","volume":"55","author":"Kreuter","year":"2020","journal-title":"Eur Respir J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2020-000563","article-title":"Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases","volume":"7","author":"Salonen","year":"2020","journal-title":"BMJ Open Respir Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-0348-0977-1_11","article-title":"Acute exacerbations of interstitial lung disease: lessons from idiopathic pulmonary fibrosis","volume":"23","author":"Spagnolo","year":"2017","journal-title":"Curr Opin Pulm Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00159709","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome","volume":"37","author":"Song","year":"2011","journal-title":"Eur Respir J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12931-016-0400-1","article-title":"Risk factors for an acute exacerbation of idiopathic pulmonary fibrosis","volume":"17","author":"Kakugawa","year":"2016","journal-title":"Respir Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12931-023-02595-z","article-title":"Animal models of acute exacerbation of pulmonary fibrosis","volume":"24","author":"Ye","year":"2023","journal-title":"Respir Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201712-2410oc","article-title":"Single-cell transcriptomic analysis of human lung provides insights into the pathobiology of pulmonary fibrosis","volume":"199","author":"Reyfman","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200810-1596oc","article-title":"Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis","volume":"180","author":"Konishi","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12890-016-0298-x","article-title":"Acute exacerbation of IPF has systemic consequences with multiple organ injury, with SRA(+) and TNF-alpha(+) cells in the systemic circulation playing central roles in multiple organ injury","volume":"16","author":"Emura","year":"2016","journal-title":"BMC Pulm Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.05.015","article-title":"Immune mechanisms in fibrotic interstitial lung disease","volume":"187","author":"Kamiya","year":"2024","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210196","article-title":"Acute exacerbations of interstitial lung diseases: focus on biomarkers","volume":"24","author":"Drakopanagiotakis","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/resp.14788","article-title":"Treatment of acute exacerbations of interstitial lung diseases with corticosteroids: evidence","volume":"29","author":"Hung","year":"2024","journal-title":"Respirology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1450688","article-title":"The immune mechanisms of acute exacerbations of idiopathic pulmonary fibrosis","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399st","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/s2213-2600(21)00354-4","article-title":"Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"10","author":"Naccache","year":"2022","journal-title":"Lancet Respir Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61091594","article-title":"Intravenous immunoglobulin in acute exacerbations of fibrotic interstitial lung diseases: a retrospective, real-world study","volume":"61","author":"Sotiropoulou","year":"2025","journal-title":"Med (Kaunas)"},{"key":"B19","article-title":"Intravenous immunoglobulin for acute exacerbation of fibrotic idiopathic interstitial pneumonias","volume":"39","author":"Higo","year":"2022","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/cells12192417","article-title":"Anti-inflammatory and immunomodulatory effect of high-dose immunoglobulins in children: from approved indications to off-label use","volume":"12","author":"Conti","year":"2023","journal-title":"Cells"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25348","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.37737\/ace.23006","article-title":"Efficacy of initial high- versus low-dose intravenous corticosteroid therapy in patients with acute exacerbation of idiopathic interstitial pneumonia: a nationwide observational study","volume":"5","author":"Awano","year":"2023","journal-title":"Ann Clin Epidemiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12931-022-02195-3","article-title":"Early corticosteroid dose tapering in patients with acute exacerbation of idiopathic pulmonary fibrosis","volume":"23","author":"Anan","year":"2022","journal-title":"Respir Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2024-222636","article-title":"Corticosteroid therapy for treating acute exacerbation of interstitial lung diseases: a systematic review","volume":"80","author":"Srivali","year":"2025","journal-title":"Thorax"},{"key":"B25","doi-asserted-by":"publisher","first-page":"A2923","DOI":"10.1164\/ajrccm.2025.211.abstracts.a2923","article-title":"Efficacy and safety of pulse versus conventional corticosteroid therapy in anti-ARS antibody-associated interstitial lung disease","volume":"211","author":"Kaburaki","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0045-2019","article-title":"The contribution of infection and the respiratory microbiome in acute exacerbations of idiopathic pulmonary fibrosis","volume":"28","author":"Invernizzi","year":"2019","journal-title":"Eur Respir Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.03.033","article-title":"The role of infection in interstitial lung diseases: a review","volume":"152","author":"Azadeh","year":"2017","journal-title":"Chest"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1581st","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2018022954","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients","volume":"2","author":"Schunemann","year":"2018","journal-title":"Blood Adv"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201701-0091oc","article-title":"Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis","volume":"196","author":"Ley","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-025-07323-0","article-title":"Treatment with nintedanib is as effective and safe in patients with other connective tissue diseases (CTDs)-interstitial lung disease (ILD) as in patients with systemic sclerosis-ILD: a multicenter retrospective study","volume":"44","author":"Misirci","year":"2025","journal-title":"Clin Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002850","article-title":"Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study","volume":"9","author":"Campochiaro","year":"2023","journal-title":"RMD Open"},{"key":"B34","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: a review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.61","article-title":"Intravenous immunoglobulin therapy in rheumatic diseases","volume":"7","author":"Bayry","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(17)30349-1","article-title":"Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study","volume":"5","author":"Herazo-Maya","year":"2017","journal-title":"Lancet Respir Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202306-0979oc","article-title":"Single-cell profiling reveals immune aberrations in progressive idiopathic pulmonary fibrosis","volume":"210","author":"Unterman","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.119.015308","article-title":"Corticosteroids added to initial intravenous immunoglobulin treatment for the prevention of coronary artery abnormalities in high-risk patients with Kawasaki disease","volume":"9","author":"Ae","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1055\/s-0043-1769087","article-title":"Efficacy and safety analysis of combination therapy consisting of intravenous immunoglobulin and corticosteroids versus respective monotherapies in the treatment of relapsed ITP in adults","volume":"10","author":"Fang","year":"2023","journal-title":"Glob Med Genet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.750173","article-title":"Intravenous immunoglobulin combined with corticosteroids for the treatment of Stevens-Johnson syndrome\/toxic epidermal necrolysis: a propensity-matched retrospective study in China","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1777564\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:02:01Z","timestamp":1780326121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1777564\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2026.1777564"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1777564","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"article-number":"1777564"}}